Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain
用于 T 型钙通道抑制的桦木酸类似物的优化,用于非成瘾性缓解慢性疼痛
基本信息
- 批准号:9907601
- 负责人:
- 金额:$ 22.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-30 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAffectAfferent NeuronsAmericanAmitriptylineAnalgesicsAntidepressive AgentsArizonaAxonBaclofenBetulinic AcidBiological AssayCalciumCalcium Channel BlockersCalcium Channel InhibitionCancer PatientCell-Mediated CytolysisCellsChemotherapy-Oncologic ProcedureChemotherapy-induced peripheral neuropathyChronicClinicalClinical TrialsComplexComplicationCoupledDose-LimitingDrug KineticsDrug TargetingDysesthesiasEffectivenessEsthesiaFeelingFiberG-Protein-Coupled ReceptorsHumanIn VitroIndigenousIon ChannelLaboratoriesLavandulaLeadMalignant NeoplasmsMediatingMediator of activation proteinMedicalMedicinal PlantsModelingMuscle relaxantsNatural ProductsNeuraxisNeuronsNeuropathyNorepinephrineNumbnessOpiate AddictionOpioidOpioid ReceptorOralPaclitaxelPainPain managementParesthesiaPathogenesisPathway interactionsPeripheralPeripheral NervesPeripheral Nervous SystemPeripheral Nervous System DiseasesPharmaceutical PreparationsPharmacologyPharmacotherapyPhasePlantsPlatinum CompoundsPrevalencePropertyProtein IsoformsProteinsQuality of lifeRattusRegimenRegulationRoleSafetySensorySerotoninShockSiteSouthwestern United StatesSpecificitySpinalSpinal CordSpinal GangliaStructureSurvival RateT-Type Calcium ChannelsTestingTissuesTranslatingTreatment ProtocolsUniversitiesVinca AlkaloidsWorkaddictionanalogbasebiophysical propertiescancer paincancer survivalcancer therapycentral sensitizationchemotherapeutic agentchemotherapychronic painchronic pain reliefchronic painful conditioncompliance behaviorcounterscreendesigndorsal horndrug discoveryduloxetineeffective therapyimprovedin vivoinhibitor/antagonistmeetingsneuronal excitabilityneurotoxicneurotoxicityneurotransmissionnon-opioid analgesicnovelnovel therapeuticsopioid misuseopioid sparingopioid usepain modelpain reliefpain signalpainful neuropathypreclinical studyreuptakescreeningsensory stimulusside effectsmall moleculesomatosensorysuccesssynaptic functiontaxanevenlafaxinevoltage
项目摘要
ABSTRACT
Chemotherapy-induced peripheral neuropathy (CIPN) is a common (prevalence 30–70%) and potentially dose-
limiting side effect of many cancer chemotherapy drug treatment regimens. Clinically, CIPN presents with pain
that is burning, shooting or electric-shock-like. The increase in prevalence of cancer coupled with an increase in
the cancer survival rates due to chemotherapy regimens is transforming cancer pain into a large, unmet medical
problem. Neurotoxic chemotherapeutic agents (e.g., antimicrotubule agents like paclitaxel) may cause structural
damage to peripheral nerves, resulting in aberrant somatosensory processing in the peripheral and/or central
nervous system. Dorsal root ganglia (DRG) sensory neurons as well as neuronal cells in the spinal cord are the
preferential sites in which chemotherapy induced neurotoxicity occurs. Pathogenesis is complex but includes
alterations in ion channels. Paclitaxel (Taxol®) increases T-type (Cav3.2) voltage-gated Ca2+ currents in rat
dorsal root ganglion (DRG) neurons; these neurons are responsible for conveying noxious sensory stimuli,
suggesting these channels are important mediators of specific sensory abnormalities associated with CIPN.
Given the roles of these channels in regulating afferent fiber excitability and synaptic function in the spinal dorsal
horn and their dynamic regulation during pain states, blocking or depleting Cav3.2 channels in these tissues
should mediate analgesic effects. In the past 5 years, considerable effort has been applied towards identifying
novel classes of T-type calcium channel blockers. This proposal aims to develop potent, orally available, and
selective Cav3.2 channel antagonists, building on the structure of a natural product – betulinic acid (BA) –
identified by the laboratory of Dr. Leslie Gunatilaka (Director, Natural Products Center, University of Arizona
(UA)) and characterized by the PI Dr. Rajesh Khanna (UA) to be Cav3.2-selective and antinociceptive in CIPN.
For this work, we have partnered with Regulonix, LLC for characterizing select Cav3.2-targeted compounds
and their analogs in in vitro and in vivo efficacy assays as well as early ADME and PK optimization. The work
proposed here is the first step in developing non-opioid pain treatments for CIPN that also curb opioid misuse
and addiction. We anticipate success against paclitaxel-induced chronic pain to translate into other chronic pain
types as well, but CIPN provides focus for early stage proof-of-concept. Regulonix’s specific aims are: (1)
Design and synthesis (Dr. L. Gunatilaka) of BA analogues and elucidation of Cav3.2 specificity and biophysical
properties of select BA analogs to gain mechanistic and safety information and to document the unique pathway
for function in neurons; (2) Profile BA analogues for their in vitro cellular cytotoxicity, early ADME and
pharmacokinetic properties, and screening for off-target effects on GPCRs, ion channels and alternative known
pain targets, including opioid receptors; and (3) Characterize the best two BA analogs, from Aim 2, for preclinical
studies using a neuropathic pain model (paclitaxel) to provide information about oral efficacy, safety, and opioid-
sparing. Upon completion, we expect to have a validated BA analog and several worthy backup compounds.
摘要
化疗引起的周围神经病变(CIPN)是一种常见的(患病率30-70%)和潜在的剂量-
限制了许多癌症化疗药物治疗方案的副作用。临床上,CIPN表现为疼痛
燃烧、射击或类似电击。癌症发病率的增加,
由于化疗方案的癌症存活率正在将癌症疼痛转化为一个巨大的,未满足的医疗需求,
问题.神经毒性化疗剂(例如,抗微管剂,如紫杉醇)可能导致结构性
外周神经损伤,导致外周和/或中枢躯体感觉处理异常
神经系统背根神经节(DRG)感觉神经元以及脊髓中的神经元细胞是脊髓的神经元。
化疗诱导的神经毒性发生的优先部位。发病机制复杂,但包括
离子通道的改变。紫杉醇(Taxol®)增加大鼠T型(Cav3.2)电压门控性Ca 2+电流
背根神经节(DRG)神经元;这些神经元负责传递有害的感觉刺激,
提示这些通道是与CIPN相关的特异性感觉异常的重要介质。
鉴于这些通道在调节脊髓背角传入纤维兴奋性和突触功能中的作用,
角和它们在疼痛状态期间的动态调节,阻断或耗尽这些组织中的Cav3.2通道
应介导镇痛作用。在过去的五年里,已经做出了相当大的努力,
新型T型钙通道阻滞剂。该提案旨在开发有效的,口服的,
选择性Cav3.2通道拮抗剂,基于天然产物桦木酸(BA)的结构,
由Leslie Gunatilaka博士(亚利桑那大学天然产品中心主任)的实验室鉴定
(UA))PI Rajesh卡纳博士(UA)将其表征为CIPN中的Cav3.2选择性和抗伤害感受性。
在这项工作中,我们与Regulonix,LLC合作,对选择的Cav3.2靶向化合物进行表征。
及其类似物在体外和体内功效测定以及早期ADME和PK优化中的应用。工作
这里提出的是为CIPN开发非阿片类药物疼痛治疗的第一步,也可以抑制阿片类药物的滥用
和上瘾。我们预计成功对抗紫杉醇引起的慢性疼痛会转化为其他慢性疼痛
类型,但CIPN为早期阶段的概念验证提供了重点。Regulonix的具体目标是:(1)
设计与合成(Dr. L. Gunatilaka)和Cav3.2特异性和生物物理学的阐明
选择BA类似物的性质,以获得机制和安全性信息,并记录独特的途径
(2)分析BA类似物的体外细胞毒性、早期ADME和
药代动力学特性,并筛选对GPCR、离子通道和已知替代药物的脱靶效应
疼痛靶点,包括阿片受体;和(3)表征来自目标2的最佳两种BA类似物,用于临床前
使用神经性疼痛模型(紫杉醇)进行研究,以提供关于口服有效性、安全性和阿片类药物的信息,
节省。完成后,我们希望有一个验证的BA类似物和几个有价值的备份化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rajesh Khanna其他文献
Rajesh Khanna的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rajesh Khanna', 18)}}的其他基金
Validation of Neuropilin-1 receptor signaling in nociceptive processing
伤害感受处理中 Neuropilin-1 受体信号传导的验证
- 批准号:
10774563 - 财政年份:2023
- 资助金额:
$ 22.47万 - 项目类别:
Antagonists of CRMP2 Phosphorylation for Chemotherapy-Induced Peripheral Neuropathy
CRMP2 磷酸化拮抗剂治疗化疗引起的周围神经病变
- 批准号:
10505802 - 财政年份:2022
- 资助金额:
$ 22.47万 - 项目类别:
Inhibition of CaVα-β interaction with orally available small organic molecules for chronic pain
抑制 CaVα-β 与口服小有机分子相互作用治疗慢性疼痛
- 批准号:
10267604 - 财政年份:2021
- 资助金额:
$ 22.47万 - 项目类别:
Sentrin proteases, CRMP2 deSUMOylation, and Chronic Pain
Sentrin 蛋白酶、CRMP2 去SUMO化和慢性疼痛
- 批准号:
10253377 - 财政年份:2021
- 资助金额:
$ 22.47万 - 项目类别:
Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain
靶向神经毡蛋白-1 受体 (NRP-1)/VEGF-A 轴治疗神经性疼痛
- 批准号:
10321851 - 财政年份:2021
- 资助金额:
$ 22.47万 - 项目类别:
CRMP2 Phosphorylation: A Novel Target for Alzheimer's Disease?
CRMP2 磷酸化:阿尔茨海默病的新靶标?
- 批准号:
10282421 - 财政年份:2021
- 资助金额:
$ 22.47万 - 项目类别:
Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain
CRMP2 磷酸化作为神经病理性疼痛新治疗靶点的遗传和药理学验证
- 批准号:
10615444 - 财政年份:2020
- 资助金额:
$ 22.47万 - 项目类别:
Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy
从多组分反应中发现T型钙通道拮抗剂及其在紫杉醇诱导的周围神经病变中的应用
- 批准号:
9552022 - 财政年份:2019
- 资助金额:
$ 22.47万 - 项目类别:
CRMP2, Nav1.7 sodium channel, and chronic pain
CRMP2、Nav1.7 钠通道和慢性疼痛
- 批准号:
9381360 - 财政年份:2017
- 资助金额:
$ 22.47万 - 项目类别:
CRMP2, Nav1.7 sodium channel, and chronic pain
CRMP2、Nav1.7 钠通道和慢性疼痛
- 批准号:
10113570 - 财政年份:2017
- 资助金额:
$ 22.47万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 22.47万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 22.47万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 22.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 22.47万 - 项目类别:
Studentship